Controlling Drug Release Through Osmotic Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlling Drug Release Through Osmotic Systems
Osmotic systems offer versatility for delivering drugs with varied properties and dosage requirements.


Pharmaceutical Technology
Volume 37, Issue 7, pp. 40-44

References
1. S.I. Shen, B.R. Jasti and X. Li, "Design of Controlled Release Drug Delivery Systems," in Standard Handbook of Biomedical Engineering & Design, M Kutz Ed. (McGraw-Hill, New York, 2003), pp. 221-235.

2. N. Basta, Pharmaceutical Commerce website, "Drug Delivery Technologies for Controlled Release Score with Manufacturers," http://pharmaceuticalcommerce.com/, accessed May 31, 2013.

3. R.K. Verma, D.M. Krishna and S. Garg, J, Control. Rel. 79 (1-3) 7-27 (2002).

4. D. Bhowmik et al., Pharma Innov. 1 (10) 24-32 (2012).

5 A. Nokhodchi et al., BioImpacts 2 (4) 175-187 (2012).

6. R.A. Siegel and M.J. Rathbone, "Overview of Controlled Release Mechanisms," in Fundamentals and Applications of Controlled Release Drug Delivery, J. Siepmann, R.A. Siegel and M.J. Rathbone Eds. (Springer, New York, 2012), pp. 19-43.

7. A. Bhargava et al., Int. J Adv. Res. Pharm. Biosci. 3 (1) 7-14 (2013).

8. A. Gauniya (2007), Pharmainfo website, "A Review on Latest Advancement in Patented Controlled/Sustained Release Drug Delivery System," http://www.pharmainfo.net/, accessed May 31, 2013.

9. D. Barbieri and E. Tocce, "Optimizing Controlled Release: The Use of Osmotic Oral Delivery Systems," Pharm. Technol. webcast, Sept. 19, 2012.

10. S. Pundir et al., Int. J Drug Res. Technol. 3 (1) 12-20 (2013).

11. P.M. Dandagi et al., Int. J Res. Pharm. Sci. 2 (2) 225-236 (2011).

12. N. Ahuja, V. Kumar and P. Rathee, Pharma Innov. 1 (7) 116-124 (2012).

13. H.M. Prajapati, S.T. Prajapati and C.N. Patel, Int. J. Pharmaceut. Res. Biosci. 1 (3) 158-194 (2012).

14. H. Patel et al., Int. Res. J Pharm. 3 (4) 88-94 (2012).

15. F. Theeuwes, J. Pharm. Sci. 64 (12) 1987-1991 (1975).

16. F. Theeuwes, "Osmotic System for Delivering Selected Beneficial Agents Having Varying Degrees of Solubility," US Patent 4111201 (Sept 1978).

17. R. Cortese and F. Theeuwes, "Osmotic Device with Hydrogel Driving Member,: US Patent 4327725 (May 1982).

18. G.M. Zentner, G.S. Rork, and K.J. Himmelstein, J. Control. Rel. 1 (4) 269-282 (1985).

19. G.M. Zentner, G.S. Rork and K.J. Himmelstein, "Controlled Porosity Osmotic Pump," European Patent 0169105 B1 (Aug 1991).

20. A.G. Thombre, G.M. Zentner, K.J. Himmelstein, J. Membr. Sci. 40 (3) 279-310 (1989).

21. A.G. Thombre et al., J. Control. Rel. 94 (1) 75-89 (2004).

22. G.M. Zentner, G. A. McClelland and S.C. Sutton, J. Control. Rel. 16 (1-2) 237-244 (1991).

23. S.M. Herbig et al., J. Control. Rel. 35 (2-3) 127-136 (1995).

24. A.K. Philip and K. Pathak, AAPS PharmSciTech 7 (3) 1-11 (2006).

25. A.K. Philip and B. Philip, PDA J. Pharm. Sci. Technol. 65(1) 32-41 (2011).

26. A.G. Thombre et al., J. Control. Rel. 57 (1) 65-73 (1999).

27. A.G. Thombre et al., J. Control. Rel. 57 (1) 55-64 (1999).

28. L. Kumar et al., Int. J. Pharm. Pharmaceut. Sci. 4 (2) 54-59 (2012).

29. N. G. Gobade, M. Koland and K. H. Harish, Indian J. Pharm. Sci. 74 (1) 69-72 (2012).

30. A.K. Philip and K. Pathak, Indian J. Pharm. Sci. 70 (6) 745-753 (2008).

31. A.K. Philip, K. Pathak, and P. Shakya, Eur. J. Pharm. Biopharm. 69 (2) 658-666 (2008).

32. S. Garg et al., Sci. Pharm. 80 (1) 229-250 (2012).

33. J. Guan et al., Pharm. Res. 27 (1) 105-114 (2010).

34. M.S. Chauhan, A. Kumar and K. Pathak, AAPS PharmSciTech 13 (4) 1492-1501 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here